Key Patent Covers Systems and Methods for Controlling Ultrasonic Energy
Applied to Skin
FRANKLIN, Mass., May 19 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that it has received a U.S. patent
covering the enabling technology employed in the SonoPrep(R) device to
precisely control skin permeability. The SonoPrep device automatically turns
off once an optimal level of skin permeability is achieved as determined by a
feedback algorithm which calculates the rate of increase in skin conductivity.
U.S. Patent No. 6,887,239 entitled "Preparation for Transmission and Reception
of Electrical Signals" was issued to Sontra on May 3, 2005.
"This patent further strengthens the intellectual property estate
surrounding the SonoPrep skin permeation technology," stated Scott Kellogg,
Sontra's Vice President of Research and Development. "This invention was a
major breakthrough for Sontra because skin properties vary from person to
person, by skin condition and location on the body. Without a practical
control mechanism we wouldn't be able to achieve consistent skin permeability
across wide demographics and skin conditions."
The SonoPrep ultrasonic skin permeation device employs low frequency
ultrasound to penetrate the skin's outermost layer, the stratum corneum. This
simple and fast (average 15 second) treatment creates an imperceptible window
through the skin that enables molecules to pass through with 100 times greater
efficiency than intact skin. SonoPrep makes the skin permeable for up to
twenty four hours for continuous non invasive diagnostics such as glucose
monitoring and transdermal drug delivery.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science.
Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with
technical competencies in transdermal drug formulation, delivery systems and
biosensors is creating a new paradigm in transdermal drug delivery and
diagnosis. The SonoPrep technology has demonstrated strong results from its
initial human clinical trials at leading universities and medical centers for
several billion dollar market opportunities including the transdermal delivery
of vaccines and large molecule drugs and continuous non-invasive glucose
monitoring. Sontra is currently marketing the SonoPrep device and procedure
tray for use with topical lidocaine to achieve rapid (within five minutes)
skin anesthesia.
Contacts:
Sean Moran, Sontra Medical CFO
508-553-8850 ext 234
or
Evan Smith, CFA / Erica Pettit, Financial Dynamics
212-850-5606 / 212-850-5614
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected benefits and efficacy
of the SonoPrep device in connection with diagnostics, vaccine delivery,
glucose monitoring and transdermal drug delivery, the expected market
opportunities, clinical study results, distribution and market acceptance of
the SonoPrep device and technology, and Sontra's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements. Such
statements are based on our current expectations and are subject to a number
of factors and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements. The
following important factors and uncertainties, among others, could cause
actual results to differ materially from those described in these forward-
looking statements: adverse results in product development, clinical trials,
commercialization efforts, product distribution and market acceptance;
difficulties or delays in obtaining regulatory approvals to market products
resulting from development efforts; difficulties or delays associated with
sources of regulatory-approved transdermal drugs and vaccines; failure to
obtain and maintain patent protection for discoveries; commercial limitations
imposed by patents owned or controlled by third parties; dependence upon
strategic partners and third-party distributors to develop, commercialize,
market and sell products based on our work; the commercial success of
products; and the requirement for substantial funding to conduct research and
development and to expand commercialization, distribution and marketing
activities. For detailed information about factors that could cause actual
results to differ materially from those described in the forward-looking
statements, please refer to Sontra's filings with the Securities and Exchange
Commission, including Sontra's most recent Quarterly Report on Form 10-QSB.
Forward-looking statements represent management's current expectations and are
inherently uncertain. We do not undertake any obligation to update forward-
looking statements made by us.
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran CFO of Sontra Medical,
+1-508-553-8850 ext 234; or Evan Smith, CFA, +1-212-850-5606, or
Erica Pettit, +1-212-850-5614, both of Financial Dynamics
|
